Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus
- First Online:
- Cite this article as:
- Hermansen, K. & Mortensen, L.S. Drug-Safety (2007) 30: 1127. doi:10.2165/00002018-200730120-00005
- 147 Downloads
The majority of patients with type 2 diabetes mellitus are overweight or obese at the time of diagnosis, and obesity is a recognised risk factor for type 2 diabetes and coronary heart disease (CHD). Conversely, weight loss has been shown to improve glycaemic control in patients with type 2 diabetes, as well as to lower the risk of CHD. The traditional pharmacotherapies for type 2 diabetes can further increase weight and this may undermine the benefits of improved glycaemic control. Furthermore, patients’ desire to avoid weight gain may jeopardise compliance with treatment, thereby limiting treatment success and indirectly increasing the risk of long-term complications. This review evaluates the influences of established and emerging therapies on bodyweight in type 2 diabetes.